Vanguard Group
ESLA icon

Vanguard Group’s Estrella Immunopharma ESLA Stock Holding History

Vanguard Group’s Portfolio ESLA Stock Details ESLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$700K Buy
448,765
+29,054
+7% +$55K ﹤0.01% 3862
2025
Q3 		$499K Buy
419,711
+136,868
+48% +$131K ﹤0.01% 3945
2025
Q2 		$242K Buy
282,843
+5,265
+2% +$5.11K ﹤0.01% 4058
2025
Q1 		$257K Buy
277,578
+255,894
+1,180% +$282K ﹤0.01% 4021
2024
Q4 		$24.5K Hold
21,684
– – ﹤0.01% 4250
2024
Q3 		$25.2K Buy
+21,684
New +$27.9K ﹤0.01% 4289

Other funds holding ESLA

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Group's ESLA Position: Q4 2025 in Review

Vanguard Group increased its Estrella Immunopharma (ESLA) stake by 6.9% in Q4 2025, buying an estimated $55K and bringing the position to 448,765 shares worth $700K. The position accounts for ﹤0.01% of the portfolio, ranked #3862.

Vanguard Group first reported a position in ESLA in Q3 2024 and has held it in 6 quarters since. 15 funds tracked by Wall St. Rank hold ESLA as of Q4 2025.

  • Vanguard Group held 448,765 shares of Estrella Immunopharma worth $700K as of Q4 2025.
  • Vanguard Group bought 29,054 Estrella Immunopharma shares in Q4 2025, an estimated $55K.
  • Estrella Immunopharma made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3862 holding.
  • Vanguard Group first reported a position in Estrella Immunopharma in Q3 2024 and has held it in 6 quarters since.
  • 15 funds tracked by Wall St. Rank held Estrella Immunopharma as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.